Navigation Links
TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire/ -- TargeGen has announced that an oral presentation of preliminary results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of Hematology (ASH) Meeting.

    Details of the presentation are as follows:

    Title:              A Phase I Study of TG101348, an Orally Bioavailable
                        JAK2-Selective Inhibitor, in Patients with
                        Myelofibrosis
    Presenter:          Dr. Animesh Pardanani, Mayo Clinic
    Session Name:       Myeloproliferative Disorders-Experimental Therapeutics
    Session Date:       Sunday, December 7, 2008
    Presentation Time:  4:30 PM
    Room:               Moscone Center SOUTH, Rooms 304-306-308
    Directions:         Howard Street entrance, turn left, up 2 flights of
                        stairs to Esplanade level

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and inflammation. Edema, angiogenesis and inflammation are involved in the pathology of many major human diseases. TargeGen initiated operations in 2002 and has raised capital from top tier venture capital sources. Current investors include VantagePoint Venture Partners, Forward Ventures, Enterprise Partners, Chicago Growth Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Management, Pappas Ventures, CTI Life Sciences and other investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030430/TARGEGENLOGO)


'/>"/>
SOURCE TargeGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
2. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
3. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
4. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
5. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
6. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
7. VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Cytopia Scientific Presentations on JAK2 Inhibitor Program
11. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. ... a federal institution supporting research in Germany ... and patient treatments at the University Clinic Heidelberg as ... The MRIdian Linac program will be headed by ... also heads radiation oncology at the German Cancer Research ...
(Date:1/19/2017)... 19, 2017   Science Exchange , the leading ... that the first five replication studies from the ... published in eLife today. Despite intense scrutiny around ... practical evaluation of reproducibility rates that may identify ... other assessments of reproducibility, the results of this ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... 2017 , ... International Protein, a company based out of Australia that focuses ... January ECRM trade show in Hilton Head, SC. , International Protein was founded ... a line of products that would elevate her fitness regime. At this ECRM trade ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... sugar-free alternative VW+ 002. The drinks have been produced in collaboration with Zlatan ... perform during your workout. , After a successful launch in Sweden last year, ...
(Date:1/20/2017)... ... 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went ... creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the age ... at 19 years of age, he joined the Navy and got married right out of ...
(Date:1/20/2017)... ... ... in Suffolk”: a story of love, secrets, and mystery. “Christmas in Suffolk” is ... works in a daycare and looks for inspiration in the local coffee shop as ... Seymour’s new book is an adventure of love and secrets. , After ...
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children and adults ... and achievable answer. “The Land of More and More” is the creation of published ... Indiana where he works with the children’s ministry department. , Michael says that ...
Breaking Medicine News(10 mins):